Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03259867
Title Combination of TATE and PD-1 Inhibitor in Liver Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Teclison Ltd.
Indications

hepatocellular carcinoma

colorectal cancer

Therapies

Nivolumab

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.